Patricia Monginoux

Virbac, Provence-Alpes-Côte d'Azur, France

Are you Patricia Monginoux?

Claim your profile

Publications (3)5.41 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: This study investigated the effects of a combination of calcium and magnesium carbonate intestinal phosphate binders, associated with natural reno-protectant substances (the uraemic toxin binder chitosan, vasoactive peptides and an extract of Astragalus membranaceus) (Pronefra®, Virbac, France) on blood parameters and mineral balance in cats. Ten cats, 2 to 5 years old at day 0, were given the supplement with their normal food for 12 weeks at 0.5ml/kg/d. Plasma creatinine and phosphorus levels decreased significantly during the study period (p=0.016, p=0.002 respectively). Fractional excretion of phosphorus was significantly lower at the end of the study than at the beginning (p=0.02), and a significant correlation (p=0.002) was found between changes in blood creatinine and changes in urinary fractional excretion of phosphorus between days 0 and 84. All calcium and magnesium blood levels remained within normal ranges throughout the study. Pronefra®, a new palatable oral supplement, was shown to be safe over 12 weeks of continuous use, and not only efficiently reduced blood phosphorus levels, but also creatinaemia. This is likely to be an indirect indicator reflecting an overall improvement of renal function. Pronefra® may, therefore, represent an interesting new supportive option in cats suffering from renal disorders from the earliest stages after diagnosis.
    Journal of Applied Research in Veterinary Medicine, The 05/2014; 12(1):8-17. · 0.44 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Intestinal phosphate binders, uremic toxin binders and some other types of supplements are an integral part of the management of chronic kidney disease (CKD) in various species, including cats. This pathology in domestic carnivores requires life-long nutritional and medical management. In this context, the compliance of owners and patients cannot be achieved without an adequate level of palatability for oral medication or supplementation. Knowing that hyporexia and anorexia are among the most commonly seen clinical signs in cats suffering from CKD this is already, in itself, a serious obstacle to acceptable compliance in sick animals. The aim of the present study was to investigate the palatability of four commercially available products designed for cats suffering from CKD: Ipakitine® (Vetoquinol, France), Azodyl® (Vetoquinol, USA), Renalzin® (Bayer, France), Rubenal® (Vetoquinol, France) and an additional recently developed product: Pronefra® (Virbac, France). The study was performed with a group of previously-characterised cats, all living in an enriched and well-being securing environment of an independent centre housing panels of pets expert in palatability measurement. In total 172 monadic testings were performed. The palatability of each product was assessed by measuring their rates of prehension and consumption, and the consumption proportions were also analysed.
    Irish Veterinary Journal 01/2014; 67(1):10. · 1.71 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: . To determine the effects of selenomethionine (Se-met) and epigallocatechin-gallate (EGCg) on gene expression, activation of mitogen-activating kinases, and DNA binding of nuclear factor-kappaB (NF-kappaB) and apolipoprotein-1 (AP-1) in articular chondrocytes. Chondrocytes, cultured in low-oxygen tension, were pretreated with L-selenomethionine or EGCg for 24 h, followed by interleukin 1 (IL-1beta) for 1 h (nuclear and cytoplasmic extracts) or 24 h (RNA extraction). Reverse transcription-polymerase chain reaction was performed to determine mRNA levels of matrix metalloproteinases (MMP-1, -3, -13), aggrecanases (-1, -2), IL-1beta, inducible nitric oxide synthase, cyclooxygenases (-1, -2), type II collagen and aggrecan, and transforming growth factor-beta (TGF-beta1, -2, -3) and their receptors I and II. Activity of mitogen-activating protein kinases (MAPK) was assayed by Western blot and AP-1/NF-kB DNA binding by electrophoretic mobility shift assay. Pretreatment with 0.5 microM Se-met prevented IL-1beta-induced MMP-1 and aggrecanase-1 expression, and reduced the cytokine inhibitory effect on type II collagen, aggrecan core protein, and TGF-beta receptor II (TGF-betaRII) mRNA levels. EGCg was more efficient in modulating the effects of IL-1beta on the genes studied. Whereas EGCg inhibited the IL-1beta-activated MAPK, NF-kappaB, and AP-1, Se-met stimulated that signaling pathway. This could account for the differential effects exerted by these antioxidants on chondrocytes. Our data provide insights into the mechanisms whereby ECGg and selenium modulate chondrocyte metabolism. Despite their differential mechanisms of action, the 2 compounds may exert global beneficial effects on articular cartilage.
    The Journal of Rheumatology 11/2005; 32(10):1958-67. · 3.26 Impact Factor